Stakeholder Views on Access to High-Cost Medicines in Australia
Author Information
Author(s): Lu Christine Y, Ritchie Jan, Williams Ken, Day Ric
Primary Institution: Harvard Medical School
Hypothesis
How can the access system for high-cost biological medicines in Australia be improved based on stakeholder opinions?
Conclusion
Stakeholders acknowledged the challenges of providing equitable access to high-cost medicines and suggested modifications to improve the Pharmaceutical Benefits Scheme.
Supporting Evidence
- Stakeholders agreed that controlled access to expensive medicines is equitable.
- Concerns were raised about the bureaucratic nature of the access scheme.
- Participants suggested that broader stakeholder consultation is necessary.
Takeaway
This study talked to people about how to make it easier for patients to get expensive medicines. They found that while the system is fair, it could be better.
Methodology
Thirty-six semi-structured interviews were conducted and analyzed thematically.
Potential Biases
Some rheumatologists had advisory roles with pharmaceutical companies, which could influence their views.
Limitations
Insights into some managerial perspectives were not obtained as administrators declined to participate.
Participant Demographics
{"age_groups":{"18-29":1,"30-39":5,"40-49":8,"50-59":14,"60+":8},"sex":{"male":13,"female":23},"stakeholder_groups":{"rheumatologist":8,"patient":6,"government_advisor":5,"public_servant":8,"consumer_representative":5,"pharmaceutical_industry_representative":3,"clinical_nurse":1}}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website